secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0000950170-24-064025
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan announces CLN-619+Keytruda shows PRs in EGFR/ALK NSCLC; monotherapy CR in parotid
--------------------------------------------------------------------------------

- Combination with pembrolizumab: 3 confirmed PRs in NSCLC (EGFR/ALK) and gastric patients typically CPI-unresponsive.
- Monotherapy: 1 CR (mucoepidermoid parotid, 71 wks), 2 PRs (endometrial), 9 SD ≥18 wks; clinical benefit rate 41.4%.
- Safety profile well tolerated; most TRAEs grade 1/2; no treatment-related deaths.
- Based on data, expansion cohorts in NSCLC initiated; Phase 1 in relapsed/refractory multiple myeloma planned.
- Data to be presented at ASCO 2024 on June 3; investor event June 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024064025/0000950170-24-064025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024064025/cgem-20240523.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-064025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer